Penserra Capital Management’s Moderna MRNA Stock Holding History

Penserra Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$0	Buy	+9	New	+$420	﹤0.01%	1155
2025 Q4	–	Sell	-18,291	Closed	-$472K	–	1116
2025 Q3	$472K	Buy	+18,291	New	+$510K	0.01%	586
2025 Q1	–	Sell	-857	Closed	-$35K	–	1132
2024 Q4	$35K	Buy	857 +827	+2,757%	+$39.5K	﹤0.01%	974
2024 Q3	$2K	Hold	30	–	–	﹤0.01%	1027
2024 Q2	$4K	Hold	30	–	–	﹤0.01%	1085
2024 Q1	$3K	Sell	30 -1,510	-98%	-$152K	﹤0.01%	1115
2023 Q4	$152K	Sell	1,540 -319	-17%	-$26.8K	﹤0.01%	819
2023 Q3	$191K	Sell	1,859 -271	-13%	-$30.2K	﹤0.01%	760
2023 Q2	$258K	Sell	2,130 -15,679	-88%	-$2.09M	0.01%	710
2023 Q1	$2.73M	Buy	17,809 +17,787	+80,850%	+$2.93M	0.06%	269
2022 Q4	$3K	Buy	+22	New	+$3.6K	﹤0.01%	1032
2021 Q4	–	Sell	-23,197	Closed	-$8.93M	–	1478
2021 Q3	$8.93M	Buy	+23,197	New	+$8.56M	0.19%	161

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Penserra Capital Management's MRNA Position: Q1 2026 in Review

Penserra Capital Management opened a new position in Moderna (MRNA) in Q1 2026: 9 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1155 among its holdings. This is a return to the name: Penserra Capital Management previously reported a position in MRNA as recently as Q3 2025.

Penserra Capital Management first reported a position in MRNA in Q3 2021 and has held it in 12 quarters since. The position peaked at $8.93M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Penserra Capital Management held 9 shares of Moderna worth $0 as of Q1 2026.
Moderna was a new Penserra Capital Management position in Q1 2026.
Moderna made up ﹤0.01% of Penserra Capital Management's portfolio in Q1 2026, its #1155 holding.
Penserra Capital Management first reported a position in Moderna in Q3 2021 and has held it in 12 quarters since.
Penserra Capital Management's Moderna position peaked at $8.93M in Q3 2021.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.